Amanda Fallin1, Alana Miller2, Kristin Ashford2. 1. College of Nursing, University of Kentucky, Lexington, KY Amanda.fallin@uky.edu. 2. College of Nursing, University of Kentucky, Lexington, KY.
Abstract
INTRODUCTION: Smoking during pregnancy is a major public health issue, contributing to adverse health outcomes. The vast majority of women with substance use disorders smoke during the perinatal period. Medication Assisted Treatment (MAT) is the standard of care for women using opioids during pregnancy. The majority of women engaged in MAT (88%-95%) report smoking. The purposes of this study were to describe: (1) facilitators and barriers to engaging in tobacco treatment among pregnant, opioid dependent women receiving MAT; and (2) strategies to tailor tobacco treatment interventions with this population. METHODS: Two semi-structured focus groups lasting approximately 45 minutes each were conducted with 22 women engaged in MAT. Focus groups were recorded, transcribed and analyzed in MAXQDA using content analysis. RESULTS: Participants reported: (1) desire to quit smoking for themselves and their children; (2) aversion to smoking; (3) a turning point in their lives from being pregnant and entering MAT; (4) nicotine dependence; (5) smoking as a way to cope with stress; (6) coping with dual dependencies; (7) past experiences with stopping smoking due to smoking restrictions; (8) perceived lack of success with nicotine replacement therapy or other tobacco treatment medications; and (9) the need for intensive environmental support for quit attempts. CONCLUSIONS: Participants were motivated to quit smoking, but faced multiple complex barriers. Integrating tobacco treatment into the psychosocial services offered in conjunction with MAT would allow a healthcare provider to offer tailored tobacco treatment in a supportive environment. IMPLICATIONS: Results of this qualitative study include facilitators and barriers to engaging in tobacco treatment among pregnant, opioid dependent women receiving MAT, as well as strategies to tailor tobacco treatment interventions for this population. In-depth knowledge of the complex barriers facing this patient population can be used to inform tailored tobacco treatment services that can be integrated into clinics providing MAT.
INTRODUCTION: Smoking during pregnancy is a major public health issue, contributing to adverse health outcomes. The vast majority of women with substance use disorders smoke during the perinatal period. Medication Assisted Treatment (MAT) is the standard of care for women using opioids during pregnancy. The majority of women engaged in MAT (88%-95%) report smoking. The purposes of this study were to describe: (1) facilitators and barriers to engaging in tobacco treatment among pregnant, opioid dependent women receiving MAT; and (2) strategies to tailor tobacco treatment interventions with this population. METHODS: Two semi-structured focus groups lasting approximately 45 minutes each were conducted with 22 women engaged in MAT. Focus groups were recorded, transcribed and analyzed in MAXQDA using content analysis. RESULTS:Participants reported: (1) desire to quit smoking for themselves and their children; (2) aversion to smoking; (3) a turning point in their lives from being pregnant and entering MAT; (4) nicotine dependence; (5) smoking as a way to cope with stress; (6) coping with dual dependencies; (7) past experiences with stopping smoking due to smoking restrictions; (8) perceived lack of success with nicotine replacement therapy or other tobacco treatment medications; and (9) the need for intensive environmental support for quit attempts. CONCLUSIONS:Participants were motivated to quit smoking, but faced multiple complex barriers. Integrating tobacco treatment into the psychosocial services offered in conjunction with MAT would allow a healthcare provider to offer tailored tobacco treatment in a supportive environment. IMPLICATIONS: Results of this qualitative study include facilitators and barriers to engaging in tobacco treatment among pregnant, opioid dependent women receiving MAT, as well as strategies to tailor tobacco treatment interventions for this population. In-depth knowledge of the complex barriers facing this patient population can be used to inform tailored tobacco treatment services that can be integrated into clinics providing MAT.
Authors: Kelly E Dunn; Stacey C Sigmon; Edward F Reimann; Gary J Badger; Sarah H Heil; Stephen T Higgins Journal: Exp Clin Psychopharmacol Date: 2010-02 Impact factor: 3.157
Authors: Joseph Biederman; MaryKate Martelon; K Yvonne Woodworth; Thomas J Spencer; Stephen V Faraone Journal: J Atten Disord Date: 2014-11-21 Impact factor: 3.256
Authors: Robin E Choo; Marilyn A Huestis; Jennifer R Schroeder; Angela S Shin; Hendrée E Jones Journal: Drug Alcohol Depend Date: 2004-09-06 Impact factor: 4.492
Authors: Katarzyna Campbell; Thomas Coleman-Haynes; Katharine Bowker; Sue E Cooper; Sarah Connelly; Tim Coleman Journal: Cochrane Database Syst Rev Date: 2020-05-22
Authors: Frank T Leone; Yuqing Zhang; Sarah Evers-Casey; A Eden Evins; Michelle N Eakin; Joelle Fathi; Kathleen Fennig; Patricia Folan; Panagis Galiatsatos; Hyma Gogineni; Stephen Kantrow; Hasmeena Kathuria; Thomas Lamphere; Enid Neptune; Manuel C Pacheco; Smita Pakhale; David Prezant; David P L Sachs; Benjamin Toll; Dona Upson; Dan Xiao; Luciane Cruz-Lopes; Izabela Fulone; Rachael L Murray; Kelly K O'Brien; Sureka Pavalagantharajah; Stephanie Ross; Yuan Zhang; Meng Zhu; Harold J Farber Journal: Am J Respir Crit Care Med Date: 2020-07-15 Impact factor: 21.405
Authors: Melissa A Jackson; Amanda L Baker; Kristen L McCarter; Amanda L Brown; Gillian S Gould; Adrian J Dunlop Journal: BMJ Open Date: 2019-11-11 Impact factor: 2.692